Literature DB >> 20166624

Effect of topical 0.5% morphine on postoperative pain after photorefractive keratectomy.

Ella G Faktorovich1, Allan I Basbaum.   

Abstract

PURPOSE: To investigate safety and efficacy of 0.5% morphine drops for pain control after photorefractive keratectomy (PRK).
METHODS: In a double-blind prospective study, 40 patients were randomized to either 0.5% morphine drops (n=20) or vehicle control (n=20). Treatment occurred every 2 hours following PRK on the day of the procedure, then four times daily on postoperative days 1 through 3. Patients completed pain assessment questionnaires (visual descriptor, numerical rating, visual analog scales, and oral analgesic consumption) every 2 hours while awake during the treatment period. Daily average and maximum scores were compared between the two groups. Patients were examined daily for 4 days after PRK, weekly for 4 weeks, then monthly for 3 months. Epithelial healing, corneal haze, and refractive outcomes were compared.
RESULTS: Both average and maximum pain scores were lower in the morphine group than in the vehicle control group on all scales and during all 4 days after PRK. Statistical significance (P<.05) was reached on numeric rating scale on procedure day and on postoperative day 1. The difference between the groups on the visual analog scale was statistically significant on procedure day, and on postoperative days 1 and 2. Oral analgesic consumption was higher in the vehicle control group on postoperative day 2. No difference between groups was noted in epithelial healing or refractive outcomes. Stromal haze scores were lower in the morphine group, but the difference was not statistically significant.
CONCLUSIONS: Topical 0.5% morphine may be an effective and safe method of pain control after PRK. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166624     DOI: 10.3928/1081597X-20100212-06

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  8 in total

1.  Co-administration of δ- and μ-opioid receptor agonists promotes peripheral opioid receptor function.

Authors:  Cicely L Schramm; Christopher N Honda
Journal:  Pain       Date:  2010-12       Impact factor: 6.961

2.  Effects of intramuscular morphine in men and women with temporomandibular disorder with myofascial pain.

Authors:  Soo-Kyung Kang; Yeon-Hee Lee; Hyeji Park; Jin Y Ro; Q-Schick Auh
Journal:  Oral Dis       Date:  2018-07-06       Impact factor: 3.511

3.  Topical morphine gel in the treatment of painful leg ulcers, a double-blind, placebo-controlled clinical trial: a pilot study.

Authors:  Salumeh Bastami; Thomas Frödin; Johan Ahlner; Srinivas Uppugunduri
Journal:  Int Wound J       Date:  2011-12-13       Impact factor: 3.315

Review 4.  Corneal Regeneration After Photorefractive Keratectomy: A Review.

Authors:  Javier Tomás-Juan; Ane Murueta-Goyena Larrañaga; Ludger Hanneken
Journal:  J Optom       Date:  2014-10-23

5.  The use of topical nalbuphine in different concentrations to control pain after photorefractive keratectomy.

Authors:  Hala Kamal Mattout; Sameh Mosaad Fouda
Journal:  Int Ophthalmol       Date:  2022-01-12       Impact factor: 2.029

6.  One-step transepithelial topography-guided ablation in the treatment of myopic astigmatism.

Authors:  Aleksandar Stojanovic; Shihao Chen; Xiangjun Chen; Filip Stojanovic; Jia Zhang; Ting Zhang; Tor Paaske Utheim
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

Review 7.  Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.

Authors:  Celia García-López; Carmen Gómez-Huertas; José-María Sánchez-González; Davide Borroni; Marina Rodríguez-Calvo-de-Mora; Vito Romano; Rahul Rachwani-Anil; Juan-Francisco Ramos-López; Santiago Ortiz-Pérez; Carlos Rocha-de-Lossada
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

8.  Efficacy of corneal cooling on postoperative pain management after photorefractive keratectomy: A contralateral eye randomized clinical trial.

Authors:  Siamak Zarei-Ghanavati; Nastaran Nosrat; Negar Morovatdar; Mojtaba Abrishami; Pardis Eghbali
Journal:  J Curr Ophthalmol       Date:  2017-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.